Business Context and Reporting Period
SciSparc Ltd. (the "Company") filed this Form 6-K on March 3, 2025, reporting a significant corporate transaction entered into on February 25, 2025. The Company, a foreign private issuer based in Tel Aviv, Israel, announced a definitive agreement to sell its subsidiary, MitoCareX Bio Ltd., a computational drug discovery company targeting resistant cancers.
Key Financial Metrics and Transaction Terms
This filing details a specific asset sale rather than general operating results. The filing text does not provide clear values for the Company's overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The financial specifics of the transaction are as follows:
- Cash Consideration: $700,000 to be paid to SciSparc upon closing.
- Equity Consideration: Shares of N2OFF, Inc. ("N2OFF") common stock representing 16.75% of N2OFF on a fully-diluted basis.
- Contingent Consideration: Potential for additional N2OFF stock representing up to 25% of N2OFF's issued and outstanding capital stock (on a fully-diluted basis) if specific milestones are achieved by December 31, 2028. SciSparc is eligible for 50% of these additional shares.
Material Changes and Transaction Structure
The primary material change is the divestiture of MitoCareX Bio Ltd. to N2OFF, Inc., resulting in MitoCareX becoming a wholly-owned subsidiary of N2OFF. Key structural elements include:
- Related Party Transaction: The agreement involves related parties, as Amitay Weiss and Liat Sidi serve as board members for both SciSparc and N2OFF. The transaction was approved by SciSparc's audit committee and board of directors.
- Closing Conditions: The transaction is contingent upon customary obligations and, critically, the approval of N2OFF's stockholders by the requisite majority.
- Termination Rights: Either party may terminate the agreement if the closing does not occur within 90 days of February 25, 2025.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the agreement and the inclusion of forward-looking statements. The filing explicitly warns that the ability to meet closing conditions and the receipt of contingent stock are subject to risks and uncertainties. Actual results may differ materially from current expectations. The Company disclaims any obligation to update these forward-looking statements. Specific risks are referenced in the Company's Annual Report on Form 20-F filed on April 1, 2024.
Investor Verification Checklist
- Verify the status of N2OFF stockholder approval required to close the transaction.
- Confirm the specific milestones defined in the agreement that trigger the issuance of the additional 25% contingent equity.
- Review the related party disclosures regarding board members Amitay Weiss and Liat Sidi to understand potential conflicts of interest.
- Monitor the 90-day termination window (expiring May 25, 2025) to assess the likelihood of deal completion.
- Examine the full text of the Securities Purchase and Exchange Agreement (Exhibit 10.1) for detailed representations and warranties.